Mixed Short Interest in Drug & Medical Stocks (June 2007)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

As you will see, the short interest changes in medical and drug stocks of the active NYSE-listed names was a bit of a mixed bag.  GlaxoSmithkline (GSK) saw the lagest increase, but its short interest is not representative of its real size or activity because it is an ADR and less active here compared to U.K. trade volume.  We ranked hese in terms of percentages with the largest increase in short interest first.

STOCK (Ticker)                JUNE07      MAY07     Change
GlaxoSmithkline (GSK)     7.74M         4.15M       +86%
Boston Scientific (BSX)   32.07M       24.06M       +33.3%
Wyeth (WYE)                          3.3M       10.37M       +28.3%
Labcorp (LH)                       4.11M         3.21M       +28%
Bristol-Myers (BMY)          26.95M       23.85M      +13%
Schering-Plough (SGP)   16.79M      15.27M       +9.9%
Medtronic (MDT)                16.11M      15.19M        +6%
Pfizer (PFE)                        54.48M       52.12M       +4.5%
Quest Diagnost. (DGX)    18.00M       17.54M       +2.6%
Merck (MRK)                       22.82M       22.55M       +1.2%
Eli Lilly (LLY)                       13.77M       14.07M        -2.1%
J&J (JNJ)                             15.37M      16.16M        -4.9%
Zimmer Holdings (ZMH)     3.89M         4.13M        -5.8%
St. Jude MEdical (STJ)        6.53M         7.13M         -8.4%
Genentech (DNA)                 6.87M         8.16M        -15.9%
Abbott Labs (ABT)              11.74M       16.39M        -28.3%

Jon C. Ogg
June 24, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618